Systemic Therapy for Prostate Cancer

Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer.

BACKGROUND: Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States. It is estimated that over 300,000 men will have been diagnosed with prostate cancer in 1996, and more than 40,000 will have died of this disease. METHODS: The authors combined their experience with a review of the literature on management of this disease ...

Systemic Delivery of Nucleic Acids for Prostate Cancer Therapy

Background Nucleic acids are emerging as a novel class of therapeutics for cancer treatment. For example, RNA interference (RNAi)based gene silencing has been widely used for identification and validation of putative cancer targets, and several RNAi nanotherapeutics are now under clinical trials in cancer patients. Messenger RNA (mRNA) has also shown unique advantages for the development of can...

N+, M0 prostate cancer: local therapy for systemic disease.

Node-positive prostate cancer without distant metastases (T any, N+, M0) currently is encountered rarely,[1-4] primarily because of the shift to diagnosis at earlier stages, a result of widespread prostate-specific antigen (PSA) testing. Because of this and the long follow-up required to reach clinically meaningful endpoints, many of the case series and almost all of the clinical trials providi...

Systemic treatment for prostate cancer.

Prostate cancer is a leading cause of cancer mortality in adult men. The majority of patients have subclinical systemic disease at diagnosis and will eventually require systemic therapy for palliation of symptoms. Recent development of new hormonal treatment options (e.g., gonadotropin-releasing hormone analogues and estramustine) has yet to demonstrate potential for improving the therapeutic i...

Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer